Cargando…

PDXK mutations cause polyneuropathy responsive to pyridoxal 5′‐phosphate supplementation

OBJECTIVE: To identify disease‐causing variants in autosomal recessive axonal polyneuropathy with optic atrophy and provide targeted replacement therapy. METHODS: We performed genome‐wide sequencing, homozygosity mapping, and segregation analysis for novel disease‐causing gene discovery. We used cir...

Descripción completa

Detalles Bibliográficos
Autores principales: Chelban, Viorica, Wilson, Matthew P., Warman Chardon, Jodi, Vandrovcova, Jana, Zanetti, M. Natalia, Zamba‐Papanicolaou, Eleni, Efthymiou, Stephanie, Pope, Simon, Conte, Maria R., Abis, Giancarlo, Liu, Yo‐Tsen, Tribollet, Eloise, Haridy, Nourelhoda A., Botía, Juan A., Ryten, Mina, Nicolaou, Paschalis, Minaidou, Anna, Christodoulou, Kyproula, Kernohan, Kristin D., Eaton, Alison, Osmond, Matthew, Ito, Yoko, Bourque, Pierre, Jepson, James E. C., Bello, Oscar, Bremner, Fion, Cordivari, Carla, Reilly, Mary M., Foiani, Martha, Heslegrave, Amanda, Zetterberg, Henrik, Heales, Simon J. R., Wood, Nicholas W., Rothman, James E., Boycott, Kym M., Mills, Philippa B., Clayton, Peter T., Houlden, Henry
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6772106/
https://www.ncbi.nlm.nih.gov/pubmed/31187503
http://dx.doi.org/10.1002/ana.25524
_version_ 1783455837534027776
author Chelban, Viorica
Wilson, Matthew P.
Warman Chardon, Jodi
Vandrovcova, Jana
Zanetti, M. Natalia
Zamba‐Papanicolaou, Eleni
Efthymiou, Stephanie
Pope, Simon
Conte, Maria R.
Abis, Giancarlo
Liu, Yo‐Tsen
Tribollet, Eloise
Haridy, Nourelhoda A.
Botía, Juan A.
Ryten, Mina
Nicolaou, Paschalis
Minaidou, Anna
Christodoulou, Kyproula
Kernohan, Kristin D.
Eaton, Alison
Osmond, Matthew
Ito, Yoko
Bourque, Pierre
Jepson, James E. C.
Bello, Oscar
Bremner, Fion
Cordivari, Carla
Reilly, Mary M.
Foiani, Martha
Heslegrave, Amanda
Zetterberg, Henrik
Heales, Simon J. R.
Wood, Nicholas W.
Rothman, James E.
Boycott, Kym M.
Mills, Philippa B.
Clayton, Peter T.
Houlden, Henry
author_facet Chelban, Viorica
Wilson, Matthew P.
Warman Chardon, Jodi
Vandrovcova, Jana
Zanetti, M. Natalia
Zamba‐Papanicolaou, Eleni
Efthymiou, Stephanie
Pope, Simon
Conte, Maria R.
Abis, Giancarlo
Liu, Yo‐Tsen
Tribollet, Eloise
Haridy, Nourelhoda A.
Botía, Juan A.
Ryten, Mina
Nicolaou, Paschalis
Minaidou, Anna
Christodoulou, Kyproula
Kernohan, Kristin D.
Eaton, Alison
Osmond, Matthew
Ito, Yoko
Bourque, Pierre
Jepson, James E. C.
Bello, Oscar
Bremner, Fion
Cordivari, Carla
Reilly, Mary M.
Foiani, Martha
Heslegrave, Amanda
Zetterberg, Henrik
Heales, Simon J. R.
Wood, Nicholas W.
Rothman, James E.
Boycott, Kym M.
Mills, Philippa B.
Clayton, Peter T.
Houlden, Henry
author_sort Chelban, Viorica
collection PubMed
description OBJECTIVE: To identify disease‐causing variants in autosomal recessive axonal polyneuropathy with optic atrophy and provide targeted replacement therapy. METHODS: We performed genome‐wide sequencing, homozygosity mapping, and segregation analysis for novel disease‐causing gene discovery. We used circular dichroism to show secondary structure changes and isothermal titration calorimetry to investigate the impact of variants on adenosine triphosphate (ATP) binding. Pathogenicity was further supported by enzymatic assays and mass spectroscopy on recombinant protein, patient‐derived fibroblasts, plasma, and erythrocytes. Response to supplementation was measured with clinical validated rating scales, electrophysiology, and biochemical quantification. RESULTS: We identified biallelic mutations in PDXK in 5 individuals from 2 unrelated families with primary axonal polyneuropathy and optic atrophy. The natural history of this disorder suggests that untreated, affected individuals become wheelchair‐bound and blind. We identified conformational rearrangement in the mutant enzyme around the ATP‐binding pocket. Low PDXK ATP binding resulted in decreased erythrocyte PDXK activity and low pyridoxal 5′‐phosphate (PLP) concentrations. We rescued the clinical and biochemical profile with PLP supplementation in 1 family, improvement in power, pain, and fatigue contributing to patients regaining their ability to walk independently during the first year of PLP normalization. INTERPRETATION: We show that mutations in PDXK cause autosomal recessive axonal peripheral polyneuropathy leading to disease via reduced PDXK enzymatic activity and low PLP. We show that the biochemical profile can be rescued with PLP supplementation associated with clinical improvement. As B(6) is a cofactor in diverse essential biological pathways, our findings may have direct implications for neuropathies of unknown etiology characterized by reduced PLP levels. ANN NEUROL 2019;86:225–240
format Online
Article
Text
id pubmed-6772106
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-67721062019-10-07 PDXK mutations cause polyneuropathy responsive to pyridoxal 5′‐phosphate supplementation Chelban, Viorica Wilson, Matthew P. Warman Chardon, Jodi Vandrovcova, Jana Zanetti, M. Natalia Zamba‐Papanicolaou, Eleni Efthymiou, Stephanie Pope, Simon Conte, Maria R. Abis, Giancarlo Liu, Yo‐Tsen Tribollet, Eloise Haridy, Nourelhoda A. Botía, Juan A. Ryten, Mina Nicolaou, Paschalis Minaidou, Anna Christodoulou, Kyproula Kernohan, Kristin D. Eaton, Alison Osmond, Matthew Ito, Yoko Bourque, Pierre Jepson, James E. C. Bello, Oscar Bremner, Fion Cordivari, Carla Reilly, Mary M. Foiani, Martha Heslegrave, Amanda Zetterberg, Henrik Heales, Simon J. R. Wood, Nicholas W. Rothman, James E. Boycott, Kym M. Mills, Philippa B. Clayton, Peter T. Houlden, Henry Ann Neurol Research Articles OBJECTIVE: To identify disease‐causing variants in autosomal recessive axonal polyneuropathy with optic atrophy and provide targeted replacement therapy. METHODS: We performed genome‐wide sequencing, homozygosity mapping, and segregation analysis for novel disease‐causing gene discovery. We used circular dichroism to show secondary structure changes and isothermal titration calorimetry to investigate the impact of variants on adenosine triphosphate (ATP) binding. Pathogenicity was further supported by enzymatic assays and mass spectroscopy on recombinant protein, patient‐derived fibroblasts, plasma, and erythrocytes. Response to supplementation was measured with clinical validated rating scales, electrophysiology, and biochemical quantification. RESULTS: We identified biallelic mutations in PDXK in 5 individuals from 2 unrelated families with primary axonal polyneuropathy and optic atrophy. The natural history of this disorder suggests that untreated, affected individuals become wheelchair‐bound and blind. We identified conformational rearrangement in the mutant enzyme around the ATP‐binding pocket. Low PDXK ATP binding resulted in decreased erythrocyte PDXK activity and low pyridoxal 5′‐phosphate (PLP) concentrations. We rescued the clinical and biochemical profile with PLP supplementation in 1 family, improvement in power, pain, and fatigue contributing to patients regaining their ability to walk independently during the first year of PLP normalization. INTERPRETATION: We show that mutations in PDXK cause autosomal recessive axonal peripheral polyneuropathy leading to disease via reduced PDXK enzymatic activity and low PLP. We show that the biochemical profile can be rescued with PLP supplementation associated with clinical improvement. As B(6) is a cofactor in diverse essential biological pathways, our findings may have direct implications for neuropathies of unknown etiology characterized by reduced PLP levels. ANN NEUROL 2019;86:225–240 John Wiley & Sons, Inc. 2019-07-01 2019-08 /pmc/articles/PMC6772106/ /pubmed/31187503 http://dx.doi.org/10.1002/ana.25524 Text en © 2019 The Authors. Annals of Neurology published by Wiley Periodicals, Inc. on behalf of American Neurological Association. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Articles
Chelban, Viorica
Wilson, Matthew P.
Warman Chardon, Jodi
Vandrovcova, Jana
Zanetti, M. Natalia
Zamba‐Papanicolaou, Eleni
Efthymiou, Stephanie
Pope, Simon
Conte, Maria R.
Abis, Giancarlo
Liu, Yo‐Tsen
Tribollet, Eloise
Haridy, Nourelhoda A.
Botía, Juan A.
Ryten, Mina
Nicolaou, Paschalis
Minaidou, Anna
Christodoulou, Kyproula
Kernohan, Kristin D.
Eaton, Alison
Osmond, Matthew
Ito, Yoko
Bourque, Pierre
Jepson, James E. C.
Bello, Oscar
Bremner, Fion
Cordivari, Carla
Reilly, Mary M.
Foiani, Martha
Heslegrave, Amanda
Zetterberg, Henrik
Heales, Simon J. R.
Wood, Nicholas W.
Rothman, James E.
Boycott, Kym M.
Mills, Philippa B.
Clayton, Peter T.
Houlden, Henry
PDXK mutations cause polyneuropathy responsive to pyridoxal 5′‐phosphate supplementation
title PDXK mutations cause polyneuropathy responsive to pyridoxal 5′‐phosphate supplementation
title_full PDXK mutations cause polyneuropathy responsive to pyridoxal 5′‐phosphate supplementation
title_fullStr PDXK mutations cause polyneuropathy responsive to pyridoxal 5′‐phosphate supplementation
title_full_unstemmed PDXK mutations cause polyneuropathy responsive to pyridoxal 5′‐phosphate supplementation
title_short PDXK mutations cause polyneuropathy responsive to pyridoxal 5′‐phosphate supplementation
title_sort pdxk mutations cause polyneuropathy responsive to pyridoxal 5′‐phosphate supplementation
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6772106/
https://www.ncbi.nlm.nih.gov/pubmed/31187503
http://dx.doi.org/10.1002/ana.25524
work_keys_str_mv AT chelbanviorica pdxkmutationscausepolyneuropathyresponsivetopyridoxal5phosphatesupplementation
AT wilsonmatthewp pdxkmutationscausepolyneuropathyresponsivetopyridoxal5phosphatesupplementation
AT warmanchardonjodi pdxkmutationscausepolyneuropathyresponsivetopyridoxal5phosphatesupplementation
AT vandrovcovajana pdxkmutationscausepolyneuropathyresponsivetopyridoxal5phosphatesupplementation
AT zanettimnatalia pdxkmutationscausepolyneuropathyresponsivetopyridoxal5phosphatesupplementation
AT zambapapanicolaoueleni pdxkmutationscausepolyneuropathyresponsivetopyridoxal5phosphatesupplementation
AT efthymioustephanie pdxkmutationscausepolyneuropathyresponsivetopyridoxal5phosphatesupplementation
AT popesimon pdxkmutationscausepolyneuropathyresponsivetopyridoxal5phosphatesupplementation
AT contemariar pdxkmutationscausepolyneuropathyresponsivetopyridoxal5phosphatesupplementation
AT abisgiancarlo pdxkmutationscausepolyneuropathyresponsivetopyridoxal5phosphatesupplementation
AT liuyotsen pdxkmutationscausepolyneuropathyresponsivetopyridoxal5phosphatesupplementation
AT tribolleteloise pdxkmutationscausepolyneuropathyresponsivetopyridoxal5phosphatesupplementation
AT haridynourelhodaa pdxkmutationscausepolyneuropathyresponsivetopyridoxal5phosphatesupplementation
AT botiajuana pdxkmutationscausepolyneuropathyresponsivetopyridoxal5phosphatesupplementation
AT rytenmina pdxkmutationscausepolyneuropathyresponsivetopyridoxal5phosphatesupplementation
AT nicolaoupaschalis pdxkmutationscausepolyneuropathyresponsivetopyridoxal5phosphatesupplementation
AT minaidouanna pdxkmutationscausepolyneuropathyresponsivetopyridoxal5phosphatesupplementation
AT christodouloukyproula pdxkmutationscausepolyneuropathyresponsivetopyridoxal5phosphatesupplementation
AT kernohankristind pdxkmutationscausepolyneuropathyresponsivetopyridoxal5phosphatesupplementation
AT eatonalison pdxkmutationscausepolyneuropathyresponsivetopyridoxal5phosphatesupplementation
AT osmondmatthew pdxkmutationscausepolyneuropathyresponsivetopyridoxal5phosphatesupplementation
AT itoyoko pdxkmutationscausepolyneuropathyresponsivetopyridoxal5phosphatesupplementation
AT bourquepierre pdxkmutationscausepolyneuropathyresponsivetopyridoxal5phosphatesupplementation
AT jepsonjamesec pdxkmutationscausepolyneuropathyresponsivetopyridoxal5phosphatesupplementation
AT bellooscar pdxkmutationscausepolyneuropathyresponsivetopyridoxal5phosphatesupplementation
AT bremnerfion pdxkmutationscausepolyneuropathyresponsivetopyridoxal5phosphatesupplementation
AT cordivaricarla pdxkmutationscausepolyneuropathyresponsivetopyridoxal5phosphatesupplementation
AT reillymarym pdxkmutationscausepolyneuropathyresponsivetopyridoxal5phosphatesupplementation
AT foianimartha pdxkmutationscausepolyneuropathyresponsivetopyridoxal5phosphatesupplementation
AT heslegraveamanda pdxkmutationscausepolyneuropathyresponsivetopyridoxal5phosphatesupplementation
AT zetterberghenrik pdxkmutationscausepolyneuropathyresponsivetopyridoxal5phosphatesupplementation
AT healessimonjr pdxkmutationscausepolyneuropathyresponsivetopyridoxal5phosphatesupplementation
AT woodnicholasw pdxkmutationscausepolyneuropathyresponsivetopyridoxal5phosphatesupplementation
AT rothmanjamese pdxkmutationscausepolyneuropathyresponsivetopyridoxal5phosphatesupplementation
AT boycottkymm pdxkmutationscausepolyneuropathyresponsivetopyridoxal5phosphatesupplementation
AT millsphilippab pdxkmutationscausepolyneuropathyresponsivetopyridoxal5phosphatesupplementation
AT claytonpetert pdxkmutationscausepolyneuropathyresponsivetopyridoxal5phosphatesupplementation
AT houldenhenry pdxkmutationscausepolyneuropathyresponsivetopyridoxal5phosphatesupplementation
AT pdxkmutationscausepolyneuropathyresponsivetopyridoxal5phosphatesupplementation